Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas

Ming Fu Chiang, Pei Yi Chou, Wan Jen Wang, Chun-I Sze, Nan-Shan Chang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidoreductase WWOX (FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor. Loss of WWOX gene expression is frequently seen in malignant cancer cells due to promoter hypermethylation, genetic alterations, and translational blockade. Intriguingly, ectopic expression of wild type WWOX preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. WWOX is known to physically bind and stabilize wild type p53. Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX. We propose that triggering WWOX activation by therapeutic drugs under p53 functional deficiency is needed to overcome TMZ resistance and induce GBM cell death.

Original languageEnglish
Article numberArticle 00043
JournalFrontiers in Oncology
Volume3 MAR
DOIs
Publication statusPublished - 2013 Dec 24

Fingerprint

temozolomide
Glioblastoma
Drug Resistance
Neoplasms
Genetic Promoter Regions
Oxidoreductases
Protein Isoforms
Cell Death
Apoptosis
Gene Expression
Therapeutics
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{fb0ed4725ca1474b886d992a193ae85a,
title = "Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas",
abstract = "Tumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidoreductase WWOX (FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor. Loss of WWOX gene expression is frequently seen in malignant cancer cells due to promoter hypermethylation, genetic alterations, and translational blockade. Intriguingly, ectopic expression of wild type WWOX preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. WWOX is known to physically bind and stabilize wild type p53. Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX. We propose that triggering WWOX activation by therapeutic drugs under p53 functional deficiency is needed to overcome TMZ resistance and induce GBM cell death.",
author = "Chiang, {Ming Fu} and Chou, {Pei Yi} and Wang, {Wan Jen} and Chun-I Sze and Nan-Shan Chang",
year = "2013",
month = "12",
day = "24",
doi = "10.3389/fonc.2013.00043",
language = "English",
volume = "3 MAR",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas. / Chiang, Ming Fu; Chou, Pei Yi; Wang, Wan Jen; Sze, Chun-I; Chang, Nan-Shan.

In: Frontiers in Oncology, Vol. 3 MAR, Article 00043, 24.12.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas

AU - Chiang, Ming Fu

AU - Chou, Pei Yi

AU - Wang, Wan Jen

AU - Sze, Chun-I

AU - Chang, Nan-Shan

PY - 2013/12/24

Y1 - 2013/12/24

N2 - Tumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidoreductase WWOX (FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor. Loss of WWOX gene expression is frequently seen in malignant cancer cells due to promoter hypermethylation, genetic alterations, and translational blockade. Intriguingly, ectopic expression of wild type WWOX preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. WWOX is known to physically bind and stabilize wild type p53. Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX. We propose that triggering WWOX activation by therapeutic drugs under p53 functional deficiency is needed to overcome TMZ resistance and induce GBM cell death.

AB - Tumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidoreductase WWOX (FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor. Loss of WWOX gene expression is frequently seen in malignant cancer cells due to promoter hypermethylation, genetic alterations, and translational blockade. Intriguingly, ectopic expression of wild type WWOX preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. WWOX is known to physically bind and stabilize wild type p53. Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX. We propose that triggering WWOX activation by therapeutic drugs under p53 functional deficiency is needed to overcome TMZ resistance and induce GBM cell death.

UR - http://www.scopus.com/inward/record.url?scp=84884228501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884228501&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00043

DO - 10.3389/fonc.2013.00043

M3 - Article

VL - 3 MAR

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 00043

ER -